Moderna Shares Rose 328% From March to October After Melanoma Vaccine Trial Results

Moderna’s share price rose 328.19% between March 2 and October 14, 2026, a period that included a sharp rally after the company reported results for a personalized melanoma vaccine. The increase also lifted the value of shares bought near the start of that period, though disclosed sales mean the full rise cannot be treated as a realized gain for the investor discussed in the source.

At the October 14 close, Moderna (NASDAQ: MRNA) traded at $226.30. It had been $52.85 on March 2, the date of the earliest known purchase by Donald Trump or his investing team. The comparison is a change in market price between two dates; it does not establish the return on the investor’s complete position.

What the disclosed trades suggest

The reported March purchase was for up to $50,000 of Moderna shares. Applying the price increase to that maximum purchase amount gives an estimated gain of as much as $164,095, for a hypothetical position worth $214,095. That calculation assumes the full $50,000 was invested at the March 2 price and that all those shares were still held at the October 14 close. The source does not establish that either condition applied to the actual holdings.

The disclosed transactions also include Moderna purchases on March 17, August 24 and August 28. Based on the source’s comparisons, shares were up 319.62% from the March 17 purchase date, 62.93% from August 24 and 64% from August 28. Those figures describe price changes from the respective dates, rather than the returns on verified individual lots of shares.

Sales complicate any estimate of the position’s total performance. The source reports sales worth up to $65,000: up to $15,000 in May and up to $50,000 in August. It says the May sale was up to $50,000 less than the amount bought by that point, and concludes that at least part of the position was likely still held by October 15. The reported ranges leave room for uncertainty about the precise number of shares retained and the realized proceeds.

That distinction matters when interpreting a large percentage move. A stock’s return between two dates can be calculated from its market prices, but an investor’s gain depends on purchase sizes and dates, sales, and the shares still held. Here, the 328.19% figure captures Moderna’s price performance from March 2 through the October 14 close. It should not be read as a confirmed return on every disclosed trade.

The August catalyst behind the move

Moderna’s gains were not evenly distributed across the period. The source attributes much of the 2026 increase to a single trading day: between August 18 and August 19, MRNA rose from $62.96 to $174.38, a jump of 176.97%. The move followed results showing that a personalized vaccine reduced the risk of melanoma recurrence and spread.

The size and timing of that rally put the March-to-October return in context. A substantial share of the measured increase occurred after the stock had spent months at much lower prices. Moderna then continued on an uptrend over the following two months, according to the source. By October 14, the stock was up 633.31% year to date.

The reported trial result concerns a specific personalized vaccine and melanoma. It provides a clear explanation for the market’s sudden reaction in August, but the share-price jump alone does not establish how the treatment will perform beyond the reported findings or what its commercial contribution will be. The source gives no further trial details, so the figures here describe the market response and the reported outcome without extending them into claims about future results.

Reading the return figures carefully

The charted comparison uses March 2 as the starting point and October 14 as the closing-price date. The article was published with October 15 as its reporting cutoff. Those dates are close, but the distinction is useful: $226.30 is the October 14 closing price, while the report describes the investor’s likely remaining position as of October 15.

For readers tracking the company, the central development is the connection between a clinical result and an unusually concentrated stock move. Moderna’s 328.19% rise from the March purchase date spans several months, but the August one-day jump did much of the work. Further interpretation depends on details absent from the source, including the full trial data and the precise quantities and prices behind the reported purchases and sales.

Featured image via Shutterstock

The post Moderna’s March-to-October stock performance appeared first on Finbold.